Oncogene-Selective Sensitivity to Synchronous Cell Death following Modulation of the Amino Acid Nutrient Cystine

Area of Science:

• Oncology
• Cell Metabolism
• Cancer Cell Biology

Background:

• Cancer cells exhibit altered metabolism, including nutrient uptake and utilization.
• Specific oncogenic mutations can influence cancer cell dependency on certain nutrients.
• Understanding nutrient-specific vulnerabilities is key to developing targeted cancer therapies.

Purpose of the Study:

• To investigate the link between amino acid nutrient availability and cancer cell viability.
• To identify specific nutrient dependencies in cancer cells driven by common oncogenes.
• To explore the therapeutic potential of nutrient deprivation in EGFR-mutant cancers.

Main Methods:

• Depletion of individual amino acid nutrients from isogenic cell lines expressing activated oncogenes.
• Analysis of cell death mechanisms, including ferroptosis and reactive oxygen species (ROS) generation.
• Inhibition of signaling pathways (EGFR, MAPK) and enzymes (NOX4) to assess their role in ferroptosis.
• In vivo studies using xenografts derived from non-small-cell lung cancer (NSCLC) models.

Main Results:

• Cystine deprivation induced significant cell death in human mammary epithelial (HME) cells with an activated epidermal growth factor receptor (EGFR) mutant.
• Cell death was identified as synchronous ferroptosis, mediated by reactive oxygen species (ROS) and hydrogen peroxide.
• Catalase, NADPH oxidase 4 (NOX4) inhibition, and blockade of EGFR or MAPK signaling protected cells from ferroptosis.
• Treatment with a cystine-depleting enzyme inhibited tumor growth in EGFR-mutant non-small-cell lung cancer (NSCLC) xenografts.

Conclusions:

• Activated EGFR signaling sensitizes cancer cells to ferroptosis upon cystine depletion.
• The EGFR/MAPK pathway plays a critical role in regulating ferroptosis sensitivity.
• Targeting cystine metabolism represents a potential therapeutic strategy for EGFR/MAPK-driven tumors.
• Cystine depletion shows promise in inhibiting the growth of EGFR-mutant NSCLC tumors.